Jardiance for NAFLD / MASLD: What the Evidence Actually Shows

What Is NAFLD / MASLD and Why Does It Matter?

Metabolic-associated steatotic liver disease (MASLD), the term adopted by international liver societies in 2023 to replace non-alcoholic fatty liver disease (NAFLD), affects roughly 25 to 30 percent of U.S. adults [1]. The condition spans a spectrum from simple hepatic steatosis to metabolic-associated steatohepatitis (MASH) and, in a subset of patients, progresses to cirrhosis and hepatocellular carcinoma. Diagnosis requires hepatic steatosis of at least 5 percent by imaging or biopsy, combined with at least one cardiometabolic risk factor such as elevated BMI, type 2 diabetes, hypertension, or dyslipidemia [2].

The metabolic overlap is large. Approximately 50 to 75 percent of people with type 2 diabetes have concurrent MASLD, and MASLD accelerates cardiovascular risk independently of other metabolic factors [3]. That convergence is exactly why SGLT2 inhibitors like empagliflozin attract interest: they target insulin resistance, visceral adiposity, and oxidative stress, all of which drive hepatic fat accumulation.

Until March 2024, no drug carried an FDA approval specifically for MASH. Resmetirom (Rezdiffra) became the first approved MASH-specific agent after the MAESTRO-NASH trial showed histologic improvement in fibrosis [4]. Empagliflozin remains off-label for MASLD, but a growing controlled-trial dataset supports its use in patients who already qualify for it on other metabolic grounds.

How Empagliflozin Works on the Liver

Empagliflozin blocks the sodium-glucose cotransporter-2 (SGLT2) in the proximal renal tubule, causing approximately 70 to 80 grams of glucose to spill into the urine per day, creating a roughly 280-kcal daily caloric deficit without requiring behavioral change [5]. That glycosuric effect lowers fasting insulin and reduces hepatic de novo lipogenesis, one of the primary drivers of intrahepatic triglyceride accumulation.

Beyond the caloric mechanism, preclinical and translational data suggest empagliflozin reduces hepatic oxidative stress, lowers circulating free fatty acid flux by reducing visceral adipose lipolysis, and may directly downregulate inflammatory pathways in hepatic Kupffer cells [6]. A 2021 meta-analysis of SGLT2 inhibitors published in the Journal of Hepatology (N = 1,197 patients across 14 trials) found reductions in serum ALT of approximately 10 IU/L and AST of approximately 8 IU/L compared with placebo or active comparators, with a statistically significant pooled effect (P<0.001) [7].

Weight loss also matters. Empagliflozin produces roughly 2 to 3 kg of body weight reduction at 24 weeks in clinical trials, and every 1 percent reduction in body weight corresponds to approximately 1 percent reduction in hepatic fat fraction on MRI-PDFF [8].

What Clinical Trials Say About Empagliflozin and Hepatic Fat

EMPA-REG OUTCOME (2015)

The key EMPA-REG OUTCOME trial (N = 7,020 adults with type 2 diabetes and established cardiovascular disease) was not designed to assess liver outcomes. It demonstrated a 38 percent relative reduction in cardiovascular death versus placebo over a median of 3.1 years [9]. However, post-hoc analyses of liver enzyme trajectories showed sustained ALT and GGT reductions in the empagliflozin arms, providing early indirect evidence of hepatic benefit in a high-risk metabolic population.

E-LIFT Trial (2019)

The E-LIFT randomized controlled trial (N = 50) assigned adults with type 2 diabetes and ultrasound-confirmed NAFLD to empagliflozin 10 mg daily or standard care for 20 weeks [10]. MRI-measured hepatic fat fraction fell by a mean of 4.0 percentage points in the empagliflozin group versus 0.5 percentage points in controls (P<0.001). ALT dropped by approximately 15 IU/L in the treatment arm. The study was small but is one of the most-cited direct liver-endpoint trials for empagliflozin.

EMPA-NAFLD Study (2021)

A 24-week double-blind RCT (N = 84) compared empagliflozin 25 mg daily to placebo in non-diabetic adults with NAFLD [11]. Hepatic fat content by controlled attenuation parameter (CAP) decreased significantly in the empagliflozin arm. The trial is notable because it enrolled patients without type 2 diabetes, broadening the potential clinical rationale beyond the glycemic indication.

Systematic Review and Meta-Analysis (Mantovani et al., 2021)

A 2021 systematic review in Diabetes Care (N = 744 patients, 8 RCTs) found that SGLT2 inhibitors as a class reduced liver fat by a mean of approximately 3.5 percentage points (95% CI: 2.1 to 5.0), reduced ALT by approximately 9 IU/L, and reduced liver stiffness on elastography [12]. Empagliflozin and dapagliflozin showed the most consistent results across studies included in the analysis.

Comparison With GLP-1 Receptor Agonists

The LEAN trial of liraglutide (N = 52) showed histologic NASH resolution in 39 percent of treated patients versus 9 percent with placebo [13]. Semaglutide 2.4 mg in the STEP-1 trial (N = 1,961) produced 14.9 percent mean weight loss, and a dedicated phase 2 NASH trial showed NASH resolution in 59 percent of patients on semaglutide 0.4 mg versus 17 percent on placebo [14]. Empagliflozin does not match those histologic resolution rates in available data, which makes it a reasonable adjunct or alternative in patients who cannot use GLP-1 agents rather than a first-choice for pure MASH treatment.

Dosing Empagliflozin for NAFLD / MASLD

Empagliflozin is commercially available as 10 mg and 25 mg once-daily oral tablets [15]. The FDA-approved starting dose for type 2 diabetes is 10 mg once daily, with optional titration to 25 mg once daily for additional glycemic effect. For heart failure and CKD, only the 10 mg dose is approved.

Liver-specific trials have used both 10 mg (E-LIFT) and 25 mg (EMPA-NAFLD). No head-to-head dose-comparison trial has been published specifically for hepatic fat endpoints. Given that the 10 mg dose produces nearly the same glycosuric effect as 25 mg in most patients, most clinicians start at 10 mg and assess tolerability and lab response at 12 weeks before considering escalation.

The drug is taken once daily with or without food. No dose adjustment is needed for hepatic impairment up to Child-Pugh class B, but it is not recommended in patients with Child-Pugh class C liver disease due to limited pharmacokinetic data and altered glucuronidation [15]. Renal function gates eligibility: empagliflozin is not recommended when eGFR falls persistently below 20 mL/min/1.73m2 for the CKD indication, though the threshold for T2D is an eGFR of at least 30 mL/min/1.73m2 [15].

HealthRX Clinical Decision Framework: Empagliflozin in MASLD

Clinicians at HealthRX use a four-checkpoint screening before prescribing empagliflozin off-label for MASLD:

1. Does the patient carry a qualifying diagnosis (T2D, HFrEF, HFpEF, or CKD with albuminuria) that justifies an FDA-approved indication? If yes, prescribe on-label and document hepatic monitoring as a secondary benefit.
2. Is baseline eGFR above 30 mL/min/1.73m2 for T2D or above 20 mL/min/1.73m2 for CKD?
3. Is the patient free of recurrent urogenital infections or history of lower-limb amputation that would raise the benefit-risk bar?
4. Is concurrent GLP-1 therapy appropriate, and if so, should both agents be combined given the additive hepatic fat reduction suggested by mechanistic data?

If all four checkpoints are favorable, empagliflozin is initiated at 10 mg daily with repeat LFTs, HbA1c, eGFR, and urine ACR at 12 weeks and every 6 months thereafter.

Monitoring Liver Response During Treatment

Liver enzyme normalization is the most accessible short-term surrogate. ALT and AST should be drawn at baseline, at 8 to 12 weeks, and at 6-month intervals. A meaningful response is generally defined as a 30 percent or greater reduction in ALT from baseline, consistent with definitions used in NASH clinical trial practice [16].

For patients with access to MRI-PDFF, a reduction below 5 percent hepatic fat fraction at 24 weeks represents a strong imaging response. Vibration-controlled transient elastography (FibroScan) at baseline and at 12 months may track fibrosis trajectory in patients with advanced MASLD (F2 or higher) [2].

HbA1c, eGFR, and urine albumin-to-creatinine ratio should be checked at every visit. The American Diabetes Association 2024 Standards of Care recommend SGLT2 inhibitors as preferred add-on therapy in type 2 diabetes when CKD, heart failure, or high cardiovascular risk coexists, independent of baseline HbA1c [17].

As the 2022 AASLD Practice Guidance on NAFLD states: "Weight loss of at least 5% is associated with steatosis improvement, and at least 7% is required for NASH resolution in most patients." Empagliflozin typically produces 2 to 3 percent body weight reduction, which is below the histologic-resolution threshold without dietary co-intervention [18]. Combining empagliflozin with a structured caloric deficit of 500 to 750 kcal per day is expected to push total weight loss into the 5 to 7 percent range that moves liver histology.

Safety Considerations Specific to MASLD Patients

Empagliflozin's overall safety profile is well-characterized across tens of thousands of trial participants [9]. Several adverse effects deserve particular attention in MASLD patients.

Genital mycotic infections occur in approximately 5 to 7 percent of women and 2 to 4 percent of men in randomized trials [9]. Patients with MASLD-associated diabetes may already have elevated susceptibility to fungal infections due to glucosuria from baseline hyperglycemia. Hygiene counseling and early treatment with topical azoles mitigates most cases.

Euglycemic diabetic ketoacidosis (euDKA) is a rare but serious risk, reported at an incidence of approximately 0.1 to 0.2 percent per year in insulin-requiring patients [15]. MASLD patients with advanced fibrosis who are on low-carbohydrate diets or who fast perioperatively carry elevated euDKA risk and should hold empagliflozin at least 3 days before elective procedures.

Volume depletion may become clinically significant in patients taking loop diuretics for concurrent heart failure. Baseline blood pressure, hydration status, and diuretic doses warrant review before initiation [15].

Lower-limb amputations were observed at a higher rate in the CANVAS trial of canagliflozin (another SGLT2 inhibitor) but not significantly elevated in EMPA-REG OUTCOME [9]. Class-wide caution is still advisable in patients with peripheral vascular disease or active foot ulcers.

Hepatotoxicity is not a recognized adverse effect of empagliflozin. The drug has not been associated with drug-induced liver injury in FDA pharmacovigilance databases, a relevant reassurance for patients already managing liver disease [15].

Insurance Coverage and Access for MASLD Patients

Empagliflozin does not have an FDA-approved indication for NAFLD or MASLD. Payers base coverage decisions on approved indications, so patients without a concurrent T2D, heart failure, or CKD diagnosis typically face denial without a qualifying comorbidity [17]. The retail cost of a 30-day supply of Jardiance 10 mg runs approximately $600 without insurance, though manufacturer savings cards (Boehringer Ingelheim's Jardiance Savings Card) can reduce out-of-pocket costs to $10 per month for commercially insured patients who qualify.

For patients who have T2D plus MASLD, documentation of both conditions in the chart and a letter of medical necessity citing trial evidence (E-LIFT, Mantovani meta-analysis) may support prior authorization appeals [10, 12]. Generic empagliflozin entered the U.S. market in 2025 after Boehringer Ingelheim's exclusivity period; generic availability is expected to substantially lower cost barriers over 12 to 24 months.

Empagliflozin vs. Other MASLD Treatment Options

Resmetirom (Rezdiffra) 80 mg or 100 mg daily is the only FDA-approved MASH-specific therapy as of 2025. MAESTRO-NASH showed histologic fibrosis improvement in 26 percent of the 80 mg group and 24 percent of the 100 mg group versus 14 percent placebo at 52 weeks (P<0.001 for both) [4]. Resmetirom targets thyroid hormone receptor-beta in the liver and is approved for non-cirrhotic MASH with moderate-to-advanced fibrosis (F2-F3). It does not address systemic metabolic risks the way empagliflozin does.

Pioglitazone 30 mg daily has the strongest histologic evidence for NASH among older agents, reducing hepatocyte ballooning and inflammation in multiple trials, though it causes approximately 2 to 4 kg of weight gain and is not ideal in patients with heart failure or osteoporosis [18]. The 2023 AASLD/EASL joint guidance notes pioglitazone as an acceptable option specifically in patients with T2D and biopsy-proven NASH.

GLP-1 receptor agonists, particularly semaglutide and liraglutide, produce larger hepatic fat reductions than empagliflozin in head-to-head and indirect comparisons, largely because of greater total weight loss [13, 14]. A 2023 network meta-analysis in Alimentary Pharmacology and Therapeutics (N = 2,648 patients, 22 RCTs) ranked semaglutide first for hepatic fat reduction, followed by liraglutide, with SGLT2 inhibitors producing meaningful but smaller effects [19].

Empagliflozin occupies a practical niche: it adds liver benefit with a favorable cardiorenal safety profile for patients already on maximally tolerated metformin plus a GLP-1 agent, or for patients who cannot tolerate GLP-1 agents due to nausea or contraindications. Combination of empagliflozin with a GLP-1 receptor agonist may produce additive hepatic fat reduction, though dedicated combination trials in MASLD remain ongoing as of mid-2025 [20].

What to Tell Patients About Timelines

Liver enzymes may begin to improve within 8 weeks of starting empagliflozin at 10 mg daily. A reduction in hepatic fat content on MRI-PDFF typically becomes detectable at 12 to 24 weeks [10, 11]. Histologic improvement, if it occurs, would not be assessed before 48 to 52 weeks in any rigorous trial design and requires biopsy confirmation. Patients should not expect symptom relief as a marker of liver response, since MASLD and early MASH are usually asymptomatic. Weight change on the scale at 8 to 12 weeks is the most accessible early indicator that the drug is producing its intended metabolic effect.

The ADA's 2024 Standards of Care state: "For patients with type 2 diabetes and established ASCVD, heart failure, or CKD, an SGLT2 inhibitor with proven cardiovascular or renal benefit is recommended regardless of baseline HbA1c or individualized HbA1c target." Patients who meet that criterion gain meaningful cardiorenal protection even before any hepatic benefit materializes [17].